B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
Open Access
- 1 January 2010
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 12 (2), R54
- https://doi.org/10.1186/ar2965
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced SclerodermaThe American Journal of Pathology, 2008
- B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic SclerosisThe American Journal of Pathology, 2006
- Attenuated liver fibrosis in the absence of B cellsJCI Insight, 2005
- B Lymphocyte Signaling Established by the CD19/CD22 Loop Regulates Autoimmunity in the Tight-Skin MouseThe American Journal of Pathology, 2004
- Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cellsArthritis & Rheumatism, 2004
- Systemic and cell type-specific gene expression patterns in scleroderma skinProceedings of the National Academy of Sciences of the United States of America, 2003
- CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouseJCI Insight, 2002
- Quantitative Genetic Variation in CD19 Expression Correlates with AutoimmunityThe Journal of Immunology, 2000
- ANTINUCLEAR ANTIBODY IN SYSTEMIC SCLEROSIS (SCLERODERMA)Rheumatic Disease Clinics of North America, 1996
- Polyclonal B lymphocyte activation in progressive systemic sclerosis.1989